48,xyyy disease: Malacards - Research Articles, Drugs, Genes, Clinical Trials

MCID: 48X005 MIFTS: 39	48,xyyy Categories: Fetal diseases, Neuronal diseases, Rare diseases, Reproductive diseases
Tissues Related diseases Publications Symptoms & Phenotypes Drugs Expand all tables

Sources

Aliases & Classifications for 48,xyyy

MalaCards integrated aliases for 48,xyyy:

Name: 48,xyyy ²⁰

48,xyyy Syndrome ⁵⁸

Classifications:

MalaCards categories:
Global: Rare diseases Fetal diseases
Anatomical: Neuronal diseases Reproductive diseases

See all MalaCards categories (disease lists)

ICD10: ³³

Congenital malformations, deformations and chromosomal abnormalities

Chromosomal abnormalities, not elsewhere classified

Other sex chromosome abnormalities, male phenotype, not elsewhere classified

Other specified sex chromosome abnormalities, male phenotype

Orphanet: ⁵⁸

Rare neurological diseases

Rare infertility disorders

Developmental anomalies during embryogenesis

External Ids:

ICD10 via Orphanet ³³ Q98.8

Orphanet ⁵⁸ ORPHA99329

Sources

Summaries for 48,xyyy

GARD : ²⁰ The following summary is from Orphanet, a European reference portal for information on rare diseases and orphan drugs.Orpha Number: 99329DefinitionA rare Y chromosome number anomaly that affects only males and is characterized by mild-moderate developmental delay (especially speech), normal to mild intellectual disability, large, irregular teeth with poor enamel, tall stature and acne. Radioulnar synostosis and clinodactyly have also been associated. Boys generally present normal genitalia, while hypogonadism and infertility is frequently reported in adult males.Visit the Orphanet disease page for more resources.

MalaCards based summary : 48,xyyy, also known as 48,xyyy syndrome, is related to 47,xyy and radioulnar synostosis, nonsyndromic. The drugs Linagliptin and Tocopherol have been mentioned in the context of this disorder. Affiliated tissues include liver, endothelial and prostate, and related phenotypes are high palate and short neck

Sources

Related Diseases for 48,xyyy

Diseases related to 48,xyyy via text searches within MalaCards or GeneCards Suite gene sharing:

#	Related Disease	Score
1	47,xyy	10.4
2	radioulnar synostosis, nonsyndromic	10.2
3	hypogonadotropic hypogonadism	10.1
4	synostosis	10.1
5	radioulnar synostosis	10.1
6	horseshoe kidney	10.1

Graphical network of the top 20 diseases related to 48,xyyy:

Sources

Symptoms & Phenotypes for 48,xyyy

Human phenotypes related to 48,xyyy:

⁵⁸ ³¹ (show all 31)

#	Description	HPO Frequency	Orphanet Frequency	HPO Source Accession
1	high palate ⁵⁸ ³¹	hallmark (90%)	Very frequent (99-80%)	HP:0000218
2	short neck ⁵⁸ ³¹	hallmark (90%)	Very frequent (99-80%)	HP:0000470
3	global developmental delay ⁵⁸ ³¹	hallmark (90%)	Very frequent (99-80%)	HP:0001263
4	depressed nasal bridge ⁵⁸ ³¹	hallmark (90%)	Very frequent (99-80%)	HP:0005280
5	hypertelorism ⁵⁸ ³¹	hallmark (90%)	Very frequent (99-80%)	HP:0000316
6	delayed speech and language development ⁵⁸ ³¹	hallmark (90%)	Very frequent (99-80%)	HP:0000750
7	pes planus ⁵⁸ ³¹	hallmark (90%)	Very frequent (99-80%)	HP:0001763
8	intellectual disability, mild ⁵⁸ ³¹	hallmark (90%)	Very frequent (99-80%)	HP:0001256
9	thick lower lip vermilion ⁵⁸ ³¹	hallmark (90%)	Very frequent (99-80%)	HP:0000179
10	recurrent upper respiratory tract infections ⁵⁸ ³¹	hallmark (90%)	Very frequent (99-80%)	HP:0002788
11	acne ⁵⁸ ³¹	hallmark (90%)	Very frequent (99-80%)	HP:0001061
12	abnormal dermatoglyphics ⁵⁸ ³¹	hallmark (90%)	Very frequent (99-80%)	HP:0007477
13	epicanthus ⁵⁸ ³¹	hallmark (90%)	Very frequent (99-80%)	HP:0000286
14	azoospermia ⁵⁸ ³¹	hallmark (90%)	Very frequent (99-80%)	HP:0000027
15	long philtrum ⁵⁸ ³¹	hallmark (90%)	Very frequent (99-80%)	HP:0000343
16	asthma ⁵⁸ ³¹	hallmark (90%)	Very frequent (99-80%)	HP:0002099
17	radioulnar synostosis ⁵⁸ ³¹	hallmark (90%)	Very frequent (99-80%)	HP:0002974
18	tall stature ⁵⁸ ³¹	hallmark (90%)	Very frequent (99-80%)	HP:0000098
19	feeding difficulties ⁵⁸ ³¹	hallmark (90%)	Very frequent (99-80%)	HP:0011968
20	dislocated radial head ⁵⁸ ³¹	hallmark (90%)	Very frequent (99-80%)	HP:0003083
21	aggressive behavior ⁵⁸ ³¹	hallmark (90%)	Very frequent (99-80%)	HP:0000718
22	abnormal renal morphology ⁵⁸ ³¹	hallmark (90%)	Very frequent (99-80%)	HP:0012210
23	low frustration tolerance ⁵⁸ ³¹	hallmark (90%)	Very frequent (99-80%)	HP:0000744
24	male hypogonadism ⁵⁸ ³¹	hallmark (90%)	Very frequent (99-80%)	HP:0000026
25	impulsivity ⁵⁸ ³¹	hallmark (90%)	Very frequent (99-80%)	HP:0100710
26	primary gonadal insufficiency ⁵⁸ ³¹	hallmark (90%)	Very frequent (99-80%)	HP:0008193
27	hypoplasia of dental enamel ⁵⁸ ³¹	hallmark (90%)	Very frequent (99-80%)	HP:0006297
28	irregularly spaced teeth ⁵⁸ ³¹	hallmark (90%)	Very frequent (99-80%)	HP:0006316
29	intellectual disability ⁵⁸		Very frequent (99-80%)
30	behavioral abnormality ⁵⁸		Very frequent (99-80%)
31	abnormality of the foot ⁵⁸		Very frequent (99-80%)

Sources

Drugs & Therapeutics for 48,xyyy

Drugs for 48,xyyy (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 1130)

Name

Status

Phase

Clinical Trials

Cas Number

PubChem Id

Linagliptin

Approved

Phase 4

668270-12-0

10096344

Tocopherol

Approved, Investigational

Phase 4

1406-66-2

Eplerenone

Approved

Phase 4

107724-20-9

150310 443872

Amantadine

Approved

Phase 4

768-94-5

2130

Rifabutin

Approved, Investigational

Phase 4

72559-06-9

6323490 46783538

Nalbuphine

Approved

Phase 4

20594-83-6

5360630 5311304

Clindamycin

Approved, Vet_approved

Phase 4

18323-44-9

29029

Lincomycin

Approved, Vet_approved

Phase 4

154-21-2

656509

Darunavir

Approved

Phase 4

635728-49-3, 206361-99-1

213039

rituximab

Approved

Phase 4

174722-31-7

10201696

Angiotensin II

Approved, Investigational

Phase 4

68521-88-0, 4474-91-3, 11128-99-7

172198

Hydrocodone

Approved, Illicit, Investigational

Phase 4

125-29-1

5284569

Abacavir

Approved, Investigational

Phase 4

136470-78-5

65140 441300

Zidovudine

Approved

Phase 4

30516-87-1

35370

Etravirine

Approved

Phase 4

269055-15-4

193962

Methadone

Approved

Phase 4

76-99-3

4095

Pioglitazone

Approved, Investigational

Phase 4

111025-46-8

4829

Buprenorphine

Approved, Illicit, Investigational, Vet_approved

Phase 4

52485-79-7

40400 644073

Aripiprazole

Approved, Investigational

Phase 4

129722-12-9

60795

Citalopram

Approved

Phase 4

59729-33-8

2771

Mirtazapine

Approved

Phase 4

85650-52-8, 61337-67-5

4205

Sertraline

Approved

Phase 4

79617-96-2

68617

Bupropion

Approved

Phase 4

34911-55-2, 34841-39-9

444

Buspirone

Approved, Investigational

Phase 4

36505-84-7

2477

Infliximab

Approved

Phase 4

170277-31-3

Mifepristone

Approved, Investigational

Phase 4

84371-65-3

55245

Misoprostol

Approved

Phase 4

59122-46-2

5282381

Montelukast

Approved

Phase 4

158966-92-8

5281040

Celecoxib

Approved, Investigational

Phase 4

169590-42-5

2662

Didanosine

Approved

Phase 4

69655-05-6

50599

Stavudine

Approved, Investigational

Phase 4

3056-17-5

18283

Ketoprofen

Approved, Vet_approved

Phase 4

22071-15-4

3825

Miconazole

Approved, Investigational, Vet_approved

Phase 4

22916-47-8

4189

Clotrimazole

Approved, Vet_approved

Phase 4

23593-75-1

2812

Voriconazole

Approved

Phase 4

137234-62-9

71616

Neomycin

Approved, Vet_approved

Phase 4

1404-04-2

8378

Fluocinolone Acetonide

Approved, Investigational, Vet_approved

Phase 4

67-73-2

6215

Iron

Approved

Phase 4

7439-89-6

23925 29936

Daptomycin

Approved, Investigational

Phase 4

103060-53-3

16129629

Tapentadol

Approved

Phase 4

175591-23-8

9838022

Vancomycin

Approved

Phase 4

1404-90-6

441141 14969

Sufentanil

Approved, Investigational

Phase 4

56030-54-7

41693

Insulin glargine

Approved

Phase 4

160337-95-1

Insulin lispro

Approved

Phase 4

133107-64-9

Ondansetron

Approved

Phase 4

99614-02-5

4595

Omalizumab

Approved, Investigational

Phase 4

242138-07-4

Budesonide

Approved

Phase 4

51333-22-3

63006 5281004

alemtuzumab

Approved, Investigational

Phase 4

216503-57-0

Acetylcysteine

Approved, Investigational

Phase 4

616-91-1

12035

Exenatide

Approved, Investigational

Phase 4

141758-74-9

15991534

Interventional clinical trials:

(show top 50) (show all 2620)

#	Name	Status	NCT ID	Phase	Drugs
1	Efficacy and Safety of Shenyankangfu Tablets for Primary Glomerulonephritis-a Multicentre, Prospective, Double-blind, Double-dummy, Randomized Controlled Clinical Trial	Unknown status	NCT02063100	Phase 4	Shenyankangfu tablets;Losartan potassium 50mg;Shenyankangfu tablets and Losartan potassium 50mg;Shenyankangfu tablets and Losartan potassium 100mg;Losartan potassium 100mg
2	A Prospective, Randomized, Multicenter, Open-label, Exploratory Study of Utilizing of "Response-Guided-Therapy (RGT)" Strategy on Optimal Nucleoside Analogue (NUC)-Experienced Patients	Unknown status	NCT02560649	Phase 4	Peginterferon alfa-2a plus Entecavir;Peginterferon alfa-2a plus Lamivudine;Peginterferon alfa-2a plus Adefovir;Peginterferon alfa-2a plus Tenofovir;Entecavir;Lamivudine;Adefovir;Tenofovir disoproxil
3	A Single Center, Prospective Phase IV, Open-Label, Randomized Trial Comparing the Efficacy , Tolerability, and Safety of Quadritherapy Regimen (Reiferon Retard® + Ribavirin + Nitazoxanide + Alfacalcidol ( Bon-One ®) ) Versus Triple Therapy Regimen (Reiferon Retard® + Ribavirin + Nitazoxanide) Versus the Standard of Care Regimen(Reiferon Retard® + Ribavirin) in the Treatment of Naïve Chronic Hepatitis- C Among the Egyptian Population. Effectiveness Will be Evaluated Based on Sustained Viral Response (SVR)	Unknown status	NCT01896609	Phase 4	Bon one in Arm 3;Xerovirinc in Arm 2;Ribavirin in Arm 1
4	Chlorhexidine Gluconate for Prevention of Ventilator Associated Pneumonia in a Pediatric Intensive Care Unit.	Unknown status	NCT01883596	Phase 4	0.12% chlorhexidine solution;Placebo
5	A Phase IV Multicenter Study of the Efficacy and Safety of 48-Week Induction Treatment With TRIZIVIR (Abacavir 300 Mg/Lamivudine 150 Mg/Zidovudine 300 Mg Combination Tablet BID) With Efavirenz (600 Mg QD) Followed by 48-Week Randomized, Open-Label, Maintenance Treatment With TRIZIVIR With or Without Efavirenz in HIV-1 Infected Antiretroviral Therapy Naive Subjects	Unknown status	NCT00011895	Phase 4	Abacavir sulfate, Lamivudine and Zidovudine;Efavirenz
6	A Multi-center, Open Label, Randomized Study of Effects and Safety Between Adefovir Dipivoxil Plus Polyene Phosphatidylcholine Capsule Versus Adefovir Dipivoxil Alone in Chronic Hepatitis B Patients	Unknown status	NCT01436539	Phase 4	Adefovir Dipivoxil and polyene phosphatidylcholine;Adefovir Dipivoxil
7	Effects of Linagliptin and Metformin Monotherapy or Combined Sequential Treatment After Early Short-term Intensive Insulin Treatment on Long-term Blood Glucose Control and Function of β Cells in Patients With Type 2 Diabetes	Unknown status	NCT03194945	Phase 4	CSII followed by Lina+MET;CSII followed by Lina;CSII followed by MET;CSII alone
8	Pegasys Plus Entecavir Versus Entecavir Versus Pegasys for Hepatitis B e Antigen-Negative Chronic Hepatitis B	Unknown status	NCT01925820	Phase 4	Pegasys&Entecavir
9	Randomised Clinical Trial to Evaluate the Obtention of Blood Samples Through an Arterial Catheter to Monitor Glycose Levels	Unknown status	NCT01176279	Phase 4
10	PRotective Effect on the Coronary Microcirculation of Patients With DIabetes by Clopidogrel or Ticagrelor	Unknown status	NCT02698618	Phase 4	Randomization
11	Placebo Controlled Study Using Lovaza as Treatment for Non-Alcoholic Fatty Liver Disease	Unknown status	NCT00941642	Phase 4	Lovaza;placebo control
12	Transfer From Methadone to Buprenorphine Maintenance Treatment Using Buprenorphine Patches: A Study on Practicability With Patients Maintained With Daily Dosages Between 60mg and 100mg Methadone.	Unknown status	NCT00750217	Phase 4	Buprenorphine patch and sublingual tablets
13	A Double-blind Randomized Trial to Compare the Efficacy of Intermittent Pneumatic Compression (IPC) With and Without Early Anticoagulant Treatment for Prevention of Venous Thromboembolism (VTE) in Patients With Acute Primary Intracerebral Hemorrhage (ICH)	Unknown status	NCT00699465	Phase 4	enoxaparin;enoxaparin placebo
14	The Impact of Early Feeding Following Ligation of the Acute Bleeding Varices	Unknown status	NCT01287702	Phase 4
15	Neutrophil gElatinase-associated Lipocalin alloWs Intensive treatMent Of cOntrast Induced Nephropathy in Patients With Urgent/Emergency Percutaneous Coronary Intervention	Unknown status	NCT01491243	Phase 4	Intensive treatment with sodium bicarbonate;Standard treatment with saline infusion
16	Prospective, Double-blinded, Randomised, Placebo Controlled Trial of Pre-emptive Analgesia to Prevent Pain Following Sternotomy for Cardiac Surgery.	Unknown status	NCT01480765	Phase 4	Pregabalin;Ketamine infusion;Placebo capsules;Placebo infusion
17	Treatment of Superficial Basal Cell Carcinoma by Topical Photodynamic Therapy With Fractionated 5-aminolevulinic Acid 20% Versus Two Stage Topical Photodynamic Therapy With Methylaminolevulinate	Unknown status	NCT01491711	Phase 4	Methylaminolevulinate PDT in 2 sessions;Fractionated 5-aminolevulinic acid hydrochloride 20% gel PDT
18	The Efficacy and Safety of the Anti Hepatitis B Placenta Transfer Factor Injection in the Treatment of HBeAg Positive Chronic Hepatitis B, Randomized, Double Blind, Placebo Controlled, Multi Center Clinical Trial	Unknown status	NCT02412319	Phase 4	Anti-HBV placenta transfer factor injection
19	Eplerenone and Aliskiren Research Targeting Hypertensive Patients With Left Ventricular Hypertrophy	Unknown status	NCT01893788	Phase 4	Aliskiren;Eplerenone
20	The Effects of Preventive Versus on Demand Nutritional Advice and Support on the Nutritional Status of Patients During Antiviral Therapy for Hepatitis C A Randomized, Multi Center Trial	Unknown status	NCT00841243	Phase 4
21	Adductor Canal Block Versus Femoral Nerve Block for Analgesia After Anterior Cruciate Ligament Reconstruction Arthroscopically	Unknown status	NCT02355093	Phase 4	ropivacaine
22	A Randomized, Placebo-Controlled, Double-Blind, Multi-Center Study to Assess the Efficacy and Safety of Fuzheng Huayu Combined With Entecavir in Liver Cirrhosis Patients Due to Hepatitis B Virus	Unknown status	NCT02241590	Phase 4	Entecavir + Placebo;Entecavir + Fuzheng Huayu Tablet
23	Efficacy and Safety of Abelmoschus Manihot for IgA Nephropathy: a Multicentre, Double-blind, Double-dummy, Randomized Controlled Trial	Unknown status	NCT02231125	Phase 4	Losartan;Abelmoschus manihot
24	A Prospective, Randomized, Multicenter, Open-label Study Evaluating HBeAg Seroconversion in HBeAg Positive CHB Patients on Treatment With NA Switched to Combined Therapy With Peginterferon Alfa-2a and NA for 48 Weeks	Unknown status	NCT02474316	Phase 4	Peginterferon alfa-2a;nucleos(t)ide analgoue
25	A Phase IV, Open Label, Multi-Center, Study of Maintenance Intravitreous Injections of Macugen (Pegaptanib Sodium) Given Every 6 Weeks for 48 Weeks in Subjects With Subfoveal Neovascular Age-Related Macular Degeneration (AMD) Initially Treated With a Modality Resulting in Maculopathy Improvement	Unknown status	NCT00354445	Phase 4	pegaptanib sodium (Macugen)
26	Open, Randomized and Multicenter Phase IV Study to Compare the Efficacy and Safety of Two Different Treatments Duration 24 Versus 48 Weeks in Chronic Hepatitis C Genotypes 2 and/or 3 co-Infected HIV-HCV Patients.	Unknown status	NCT00611819	Phase 4	Peg interferon + Ribavirin;Peg interferon + Ribavirin
27	An Open-Label, Multicenter Study to Evaluate the Efficacy and Safety of a Fixed-Dose Combination of Abacavir 600 mg/Lamivudine 300 mg Once-Daily in Combination With Atazanavir 300 mg + Ritonavir 100 mg Once-Daily in Antiretroviral-Naïve HIV-1 Infected Subjects With Continuing Evaluation of Abacavir/Lamivudine Plus Atazanavir 400 mg for Maintenance Over an Additional 48 Weeks	Unknown status	NCT00426296	Phase 4	atazanavir (Reyataz);ritonavir (Norvir)
28	Randomized, Multi-Center, Partially Placebo-Controlled Phase IV-Study to Compare Efficacy and Tolerability of 48-Week Combined Therapy With Peginterferon Alfa-2a, Ribavirin and Amantadine Sulphate Versus Placebo in Untreated Patients With Chronic Hepatitis C Virus-Genotype-1-Infection	Unknown status	NCT00127777	Phase 4	Amantadine sulphate (in addition to standard treatment)
29	Efficacy and Safety of an Initial Regimen Raltegravir (RAL) + Lamivudine/Abacavir Fixed-Dose Combination (3TC/ABC FDC) for 48 Weeks in ART-naïve, HIV/TB Co-Infected Adult Subjects Receiving Rifabutin-containing, 1-line Anti-TB Therapy	Unknown status	NCT01059422	Phase 4	Raltegravir; Abacavir/Lamivudine
30	Open Label Phase 4, 48 Week Pilot Study of the Antiviral Efficacy and Tolerability of the Combination of Isentress™ and ReyatazTM When Substituted for Current Antiviral Regimen in Patients With Viral Suppression But Who Are Experiencing Adverse Events Related to Their Current Antiviral Regimen.	Unknown status	NCT00751153	Phase 4	Raltegravir and Atazanavir
31	A Phase IV 48 Week, Open Label, Pilot Study of Darunavir Boosted by Cobicistat in Combination With Rilpivirine to Treat HIV+ Naïve Subjects (PREZENT)	Unknown status	NCT02404233	Phase 4	darunavir/cobicistat;rilpivirine
32	An Open Label, Randomized, Parallel Design Estimation Pilot Study to Compare the Effectiveness of 36 vs 48 Wks PegIntron Plus Ribavirin Treatment for HCV Patients Without Rapid Virologic Response(RVR) But With Undetectable HCV RNA at wk 8	Unknown status	NCT01683786	Phase 4	Pegintron + Riba
33	Multi-center, Randomized, Open Label, Comparative, Phase IV Study to Evaluate the Efficacy and Safety of a Combination of Mycophenolate Mofetil and Corticosteroid for 48 Weeks in Advanced IgA Nephropathy	Unknown status	NCT02981212	Phase 4	Mycophenolate Mofetil;ACE inhibitor;Corticosteroid;ARB
34	Cost-effectiveness of Different Antiretroviral Treatment in Patients HIV Naive. Randomized Clinical, Not Masked, Trial Comparing DRVr3TC, ABC3TC (Kivexa) RPV, or EVG COBI FTC TDF (Stribild) for 48 Weeks	Unknown status	NCT02470650	Phase 4	elvitegravir/cobicistat/emtricitabine/tenofovir;Darunavir;abacavir/lamivudine;Ritonavir;Lamivudine;rilpivirine
35	A Randomized Controlled Trial to Compare the Efficacy and Safety of NALDEBAIN With Intravenous Patient-Controlled Analgesia With Fentanyl for the Treatment of Post-Laparotomy Surgery	Unknown status	NCT03296488	Phase 4	Nalbuphine Sebacate;Fentanyl Citrate
36	A Randomized, Controlled, Open-label, Multicenter Clinical Trial to Evaluate the Addition of PegIFN Alfa-2a to CHB Patients Treated With Nucleot(s)Ides	Unknown status	NCT02644538	Phase 4	PegIFN alfa-2a
37	An Open-Label, Comparative, Randomized, Prospective Study To Compare Sirolimus Versus Tacrolimus In De Novo Simultaneous Pancreas- Kidney Allograft Recipients Receiving An Induction Therapy With Antithymocyte Globulin Plus Mycophenolate Mofetil Plus Corticosteroids	Unknown status	NCT00693446	Phase 4	Sirolimus;Tacrolimus
38	Artemether/ Lumefantrine: A Study of the Effect of Local Food on Pharmacokinetics of Lumefantrine and Population Pharmacokinetics of Lumefantrine Among Ugandan Children	Unknown status	NCT01944189	Phase 4
39	An Open Pilot Study to Evaluate the Efficacy and Safety, Tolerability of Raltegravir（RAL）in Treatment-experienced HIV-1 Infected Adult Chinese Patients	Unknown status	NCT01201239	Phase 4	raltegravir
40	A Double Blind Randomised Control Trial to Measure the Effect of the Addition of Clindamycin to Flucloxacillin for the Treatment of Limb Cellulitis	Unknown status	NCT01876628	Phase 4	Flucloxacillin and Clindamycin;Flucloxacillin and placebo
41	A Pilot Randomized, Open Label Study to Evaluate Efficacy and Safety of the Combination of RAL+ATV/r in Comparison With TDF/FTC+ATV/r in HIV Infected Patients, Who Failed an Initial NNRTI Containing Regimen	Unknown status	NCT01829802	Phase 4	Ritonavir boosted Atazanavir;Raltegravir;TDF/FTC (or 3TC)
42	Pleiotropic Effects and Safety of Sodium Glucose Co-transporter 2 Inhibitor Versus Sulfonylurea in Patients With Type 2 Diabetes and Non-alcoholic Fatty Liver	Unknown status	NCT02649465	Phase 4	Tofogliflozin;Glimepiride
43	Long-acting Granulocyte Colony Stimulating Factor for the Prevention of Febrile Neutropenia in Gynecologic Cancer Patients: A Prospective Cohort Study	Unknown status	NCT03793205	Phase 4	Long-acting G-CSF;Short-acting G-CSF
44	The Effectiveness, Safety, and Acceptability of Home-administered Medical Abortion at Gestational Age of 8 to ≤9 Weeks Versus >9 to ≤12 Weeks: A Prospective Cohort Study in Mexico City	Unknown status	NCT02745093	Phase 4	Mifepristone;Misoprostol
45	A Multicenter, Randomized, Open-label Control Study to Evaluate Efficacy and Safety of Combination Therapy of Thymalfasin and Entecavir in HBeAg-positive ETV-experienced Patients	Unknown status	NCT03448744	Phase 4	Thymosin Alpha1;Entecavir
46	Endoesophageal Cryotherapy: A New Technique For Ablating Barrett's Esophagus And Early Stage Esophageal Cancer	Unknown status	NCT00628784	Phase 4
47	Rationale, Design and Methods for the Early Surgery in Infective Endocarditis Study: a Multicenter, Prospective, Randomized Trial Comparing the State-of-the-Art Therapeutic Strategy Versus Early Surgery Strategy in Infective Endocarditis	Unknown status	NCT00624091	Phase 4
48	Serum Level Measurement of Oral Paracetamol and Oral Ibuprofen	Unknown status	NCT01544972	Phase 4	Oral paracetamol;Oral ibuprofen
49	Clinical, Microbiological and Biochemical Effects of the Antimicrobial Photodynamic Therapy	Unknown status	NCT01532674	Phase 4
50	Albumin Infusion Effects in Mortality in Patients With Cirrhosis and Hepatic Encephalopathy	Unknown status	NCT02401490	Phase 4	Human albumin;Placebo

Search NIH Clinical Center for 48,xyyy

Sources

Genetic Tests for 48,xyyy

Sources

Anatomical Context for 48,xyyy

MalaCards organs/tissues related to 48,xyyy:

⁴⁰

Liver, Endothelial, Prostate, Skin, Kidney, Spinal Cord, Bone

Sources

Publications for 48,xyyy

Articles related to 48,xyyy:

(show top 50) (show all 30000)

#	Title	Authors	PMID	Year
1	Neferine improves oxidative stress and apoptosis in benign prostate hyperplasia via Nrf2-ARE pathway. ⁶¹	Jahan N...Wang S	33416009	2021
2	A genome-wide survey of interaction between rice and Magnaporthe oryzae via microarray analysis. ⁶¹	Tan Y...Liu X	33356807	2021
3	Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2M), 48-week results: a randomised, multicentre, open-label, phase 3b, non-inferiority study. ⁶¹	Overton ET...Spreen W	33308425	2021
4	Immediate Effect of Ankle Mobilization on Range of Motion, Dynamic Knee Valgus, and Knee Pain in Women With Patellofemoral Pain and Ankle Dorsiflexion Restriction: A Randomized Controlled Trial With 48-Hour Follow-Up. ⁶¹	Coelho BAL...Joao SMA	33373976	2021
5	Impact of germination on phenolic composition, antioxidant properties, antinutritional factors, mineral content and Maillard reaction products of malted quinoa flour. ⁶¹	Bhinder S...Singh N	33418417	2021
6	Forecasting individual risk for long-term Posttraumatic Stress Disorder in emergency medical settings using biomedical data: A machine learning multicenter cohort study. ⁶¹	Schultebraucks K...van Zuiden M	33553513	2021
7	Analyses of microRNAs and transcriptomes in the midgut of Spodoptera litura feeding on Brassica juncea. ⁶¹	Zou XP...Zheng SC	32166878	2021
8	Changes to hepatic nutrient dynamics and energetics in rainbow trout (Oncorhynchus mykiss) following exposure to and recovery from hydraulic fracturing flowback and produced water. ⁶¹	Weinrauch AM...Blewett TA	33127144	2021
9	Efficacy of atrazine pesticide reduction in aqueous solution using activated carbon, ozone and a combination of both. ⁶¹	Aldeguer Esquerdo A...Prats Rico D	33385651	2021
10	Matrix composition during ozonation of N-containing substances may influence the acute toxicity towards Daphnia magna. ⁶¹	Wirzberger V...Schmidt TC	33129546	2021
11	COVID-19 screening test by using random oropharyngeal saliva. ⁶¹	Rao M...Ahmad N	33393672	2021
12	Selective-cerebral-hypothermia-induced neuroprotection against-focal cerebral ischemia/reperfusion injury is associated with an increase in SUMO2/3 conjugation. ⁶¹	Sun G...Wang M	33539797	2021
13	Effects of Good Pain Management (GPM) ward program on patterns of care and pain control in patients with cancer pain in Taiwan. ⁶¹	Su WC...Wang JY	32803728	2021
14	Silver Nanoparticles Synthesized Using Carica papaya Leaf Extract (AgNPs-PLE) Causes Cell Cycle Arrest and Apoptosis in Human Prostate (DU145) Cancer Cells. ⁶¹	Singh SP...Acharya A	32557113	2021
15	Holmium phosphate nanoparticles as negative contrast agents for high-field magnetic resonance imaging: Synthesis, magnetic relaxivity study and in vivo evaluation. ⁶¹	Gomez-Gonzalez E...Becerro AI	33360885	2021
16	Data on DNA-seq analysis of Endophytic Streptomyces sp. SUK 48. ⁶¹	Ahmad SJ...Zin NM	33604422	2021
17	Impact of a Family Economic Intervention (Bridges) on Health Functioning of Adolescents Orphaned by HIV/AIDS: A 5-Year (2012-2017) Cluster Randomized Controlled Trial in Uganda. ⁶¹	Ssewamala FM...Brooks-Gunn J	33476237	2021
18	Primary adjunctive corticosteroid therapy is associated with improved outcomes for patients with Kawasaki disease with coronary artery aneurysms at diagnosis. ⁶¹	Friedman KG...Newburger JW	32943389	2021
19	Influence of the flooded time on the performance of a tidal flow constructed wetland treating urban stream water. ⁶¹	Roth JJ...Carvalho KQ	33248753	2021
20	Feasibility assessment of outpatient colorectal resections at a tertiary referral center. ⁶¹	Studniarek A...Marecik SJ	33094353	2021
21	Timing and Type of Venous Thromboembolic Prophylaxis in Isolated Severe Liver Injury Managed Non-Operatively. ⁶¹	Jakob DA...Demetriades D	33211165	2021
22	Environmental persistence of equid herpesvirus type-1. ⁶¹	Saklou NT...Goehring LS	32557765	2021
23	Association of fibre degradation with ruminal dissolved hydrogen in growing beef bulls fed with two types of forages. ⁶¹	Wang R...Tan ZL	32718369	2021
24	Characterizing imidacloprid and metabolites in songbird blood with applications for diagnosing field exposures. ⁶¹	Eng ML...Morrissey CA	33218798	2021
25	Predicting Functional Outcomes and Length of Stay Following Acoustic Neuroma Resection. ⁶¹	Moshtaghi O...Friedman RA	32757415	2021
26	Antisclerothic effect of tibolone by reducing proinflammatory cytokines expression, ROS production and LDL-ox uptake in THP-1 macrophages. ⁶¹	Aguayo-Ceron KA...Calzada-Mendoza CC	33383063	2021
27	Determination of Cerebrovascular Accident Predictors in Patients with New-Onset Atrial Fibrillation After Coronary Artery Bypass Graft Surgery. ⁶¹	Demir AR...Erturk M	33450607	2021
28	Depressed Older Patients with Death Wishes: Experimental Evidence for Psychotherapists' Age and Health Bias. ⁶¹	Kessler EM...Schafer T	33275085	2021
29	Clinical Presentation and Outcome of Patients With Spontaneous Coronary Artery Dissection Versus Atherosclerotic Coronary Plaque Dissection. ⁶¹	Daoulah A...Lotfi A	32657974	2021
30	A phase 2 multicenter study of ublituximab, a novel glycoengineered anti-CD20 monoclonal antibody, in patients with relapsing forms of multiple sclerosis. ⁶¹	Fox E...Inglese M	32351164	2021
31	Comparison of conventional autopsy with post-mortem magnetic resonance, computed tomography in determining the cause of unexplained death. ⁶¹	Femia G...Puranik R	33464532	2021
32	Ultrasound assessment of the cervix in predicting successful membrane sweeping: a prospective observational study. ⁶¹	Rizzo G...D'Antonio F	31092080	2021
33	Contribution of perfusion to the 11 C-acetate signal in brown adipose tissue assessed by DCE-MRI and 68 Ga-DOTA PET in a rat model. ⁶¹	Richard G...Lepage M	33010059	2021
34	Bisphosphonate Versus Bisphosphonate and Calcitonin for the Treatment of Moderate to Severe Hypercalcemia of Malignancy. ⁶¹	Khan AA...DeMott JM	32885992	2021
35	Impaired interferon-α expression in plasmacytoid dendritic cells in asthma. ⁶¹	Lin TY...Lin HC	33236850	2021
36	The association between ozone and years of life lost from stroke, 2013-2017: A retrospective regression analysis in 48 major Chinese cities. ⁶¹	Li J...Zhou M	33092875	2021
37	Tirofiban combined with heparin's effect and safety in the treatment of mild to moderate acute ischemic stroke. ⁶¹	Qiu T...Chen M	33274689	2021
38	Ambient sulfur dioxide and years of life lost from stroke in China: a time-series analysis in 48 cities. ⁶¹	Wu Z...Li G	33183785	2021
39	Ventricular arrhythmias in Takotsubo Syndrome: incidence, predictors and clinical outcomes. ⁶¹	Pelargonio G...Crea F	32890232	2021
40	Prognosis and Circumferential Margin in Patients with Resected Hilar Cholangiocarcinoma. ⁶¹	Stremitzer S...Malik HZ	32914390	2021
41	Masculinization in common carp (Cyprinus carpio) by androgen immersion: The interaction effect of hormone concentration and immersion time. ⁶¹	Asad F...Mustafa G	32901653	2021
42	Incidence and long-term outcomes of pregnant women complicated with pulmonary arterial hypertension during different pregnancies: A prospective cohort study from China. ⁶¹	Yang M...Lin J	33053388	2021
43	Prediction, identification and progression of histopathological liver disease activity in children with intestinal failure. ⁶¹	Mutanen A...Pakarinen MP	33002568	2021
44	Pediatric Feeding Disorder in Children With Short Bowel Syndrome. ⁶¹	Christian VJ...Goday PS	33003167	2021
45	Prognostic value of pretreatment plasma D-dimer level in dogs with intermediate to high-grade non-Hodgkin lymphoma. ⁶¹	Boye P...Tierny D	32643242	2021
46	Recovery of Inflammation, Cardiac, and Muscle Damage Biomarkers After Running a Marathon. ⁶¹	Bernat-Adell MD...Hernando-Domingo C	31045685	2021
47	Magnetic resonance imaging differentiates locoregional flaps from free flaps after reconstructive surgical treatment of tongue cancer. ⁶¹	Xu Q...Cao D	32855103	2021
48	Multi-sample measurement of hyperpolarized pyruvate-to-lactate flux in melanoma cells. ⁶¹	Lees H...Keshari KR	33314422	2021
49	Relationship between detection of hepatitis B virus in saliva and periodontal disease in hepatitis B virus carriers in Japan. ⁶¹	Kamimura H...Terai S	33183962	2021
50	COVID-19 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in children and adolescents: a systematic review of critically unwell children and the association with underlying comorbidities. ⁶¹	Williams N...Gupta A	32914200	2021

Sources

Genes for 48,xyyy

Sources

Variations for 48,xyyy

Sources

Expression for 48,xyyy

Search GEO for disease gene expression data for 48,xyyy.

Sources

Pathways for 48,xyyy

Sources

GO Terms for 48,xyyy

Sources

Sources for 48,xyyy

¹ BioSystems

² BitterDB

³ CDC

⁴ Cell Signaling Technology

⁵ ClinicalTrials

⁶ ClinVar

⁷ CNVD

⁸ Cochrane Library

⁹ Cosmic

¹⁰ dbSNP

¹¹ DGIdb

¹² Disease Ontology

¹³ diseasecard

¹⁴ DiseaseEnhancer

¹⁵ DISEASES

¹⁶ DrugBank

¹⁷ EFO

¹⁸ ExPASy

¹⁹ FMA

²⁰ GARD

²¹ GeneAnalytics

²² GeneCards

²³ GeneGo (Thomson Reuters)

²⁴ GeneHancer via GeneCards

²⁵ GeneReviews

²⁶ GenomeRNAi

²⁷ GEO DataSets

²⁸ GO

²⁹ GTR

³⁰ HMDB

³¹ HPO

³² ICD10

³³ ICD10 via Orphanet

³⁴ ICD9CM

³⁵ IUPHAR

³⁶ KEGG

³⁷ LifeMap

³⁸ LncRNADisease

³⁹ LOVD

⁴⁰ MalaCards

⁴¹ MedGen

⁴² MedlinePlus

⁴³ MedlinePlus Genetics

⁴⁴ MeSH

⁴⁵ MESH via Orphanet

⁴⁶ MGI

⁴⁷ miR2Disease

⁴⁸ NCBI Bookshelf

⁴⁹ NCI

⁵⁰ NCIt

⁵¹ NDF-RT

⁵² NIH Clinical Center

⁵³ NINDS

⁵⁴ Novoseek

⁵⁵ Novus Biologicals

⁵⁶ OMIM via Orphanet

⁵⁷ OMIM® (Updated 05-Mar-2021)

⁵⁸ Orphanet

⁵⁹ PathCards

⁶⁰ PharmGKB

⁶¹ PubMed

⁶² PubMed Health

⁶³ QIAGEN

⁶⁴ R&D Systems

⁶⁵ Reactome

⁶⁶ Sino Biological

⁶⁷ SNOMED-CT

⁶⁸ SNOMED-CT via HPO

⁶⁹ TGDB

⁷⁰ Tocris

⁷¹ UMLS

⁷² UMLS via Orphanet

⁷³ UniProtKB/Swiss-Prot

⁷⁴ Wikipedia